CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » BLOGS

ONCOLOGY. Vol. 26 No. 4
THE CHEERFUL ONCOLOGIST 

“I’m Not Going to Treat Your Cancer”

By Craig R. Hildreth, MD | March 30, 2012
Dr. Hildreth is a medical oncologist in private practice.

Of all the sad pronouncements that oncologists deliver, this may be the one that stings the most.

Dr. Hildreth is a medical oncologist in private practice

If you were expecting hope from your doctor, how would you react to these words? Would you sit with quiet disbelief, or storm out of the office? Why would putative healers, trained to ravage cancer at every turn, back away from a new opportunity? I recently had to tell a nice patient this distressing news almost immediately after he was diagnosed; in fact it was during just our second visit together. When I walked into the exam room on that day I was stunned to realize that our chance to work together was gone, and at first it angered me. While counseling the family, though, I was overwhelmed by a sense of shame, as if by refusing to treat my patient I was mocking his life. Nevertheless, our discussion led on inexorably to his agreeing to hospice care. What then is the rationale behind oncologists recommending that cancer be allowed to take its natural course?

(MORE: “This Is My Last Day on Earth”)

The answers seem intuitive, but since this decision is difficult to make and can cause great distress to patients and their families, let’s spend a moment reviewing the circumstances under which oncologists recommend avoiding treatment.

“You are too sick to tolerate the treatment.”

With advances in chemotherapy and biological agents appearing almost monthly now, this is the most common reason why we advise no therapy. The risk of not surviving the toxicity of chemotherapy rises, and the likelihood that life will be prolonged falls when patients who are disabled attempt treatment. By disabled I mean patients who because of their symptoms require help with daily activities that we take for granted, such as getting out of bed by ourselves. Another discouraging sign is when patients spend the majority of their time resting during the daylight hours. This decline is what prompted me to recommend hospice care to my new patient.

“Treatment has no chance to improve your life.”

Again, this is a common sense ruling—if a patient is obtunded, demented, bedridden, unable to cooperate with instructions or incapable of understanding the treatment, I won’t proceed with aggressive therapy. This does not preclude certain palliative measures to relieve suffering, such as radiation therapy.

“There are no effective treatments available for you.”

The key word here is effective. One of the quirks oncologists possess is a short-sighted enthusiasm to keep trying new chemotherapy drugs, also known as “Don’t give up the ship!” Such misguided attempts at throwing new drugs at patients, with little chance of response, are better termed “rearranging deck chairs on the Titanic.”

We have deserved such criticism in the past, but now the world has awakened to the value of appropriate end-of-life care. Oncologists, therefore, are obligated to stop treating when treatments have stopped working, and avoid any pressure to provide futile therapy.

One final note—as in all patient care, there are exceptions to the rules. If you were to present with a certain type of cancer, even if you were critically ill, in intensive care, on a ventilator, hypotensive, sedated and unable to receive informed consent, I would still treat you. In fact, with the permission of your family I would start you on chemotherapy today. What is unique about your case? You have a highly curable malignancy, such as Hodgkin lymphoma, one that will die from my treatment faster than it can kill you. Among many others, such are things that make oncologists smile.

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.

  • Oldest First
  • Newest First

by arnold wax | April 06, 2012 10:47 PM EDT

Great blog. Your attitude is the one all onologists should have, but unfortunately most lack. They have not learned the prime directive of primum non nocere (do no harm). Whenever an oncolgist "it's all about the patient"one can safely translate that into "it's all about the money." The lack of short term and long term respect for the drugs and chemiicals we use is mind boggling. Itis unfortunate that credentialing based upon outcome, and economics is not routinely used. Long survivals are more often about the natural history of the disease, rather than our treatments. This is especially true for incurable diseases. When we all realize that response rates and progression free survival rates do not translate into health outcome benefits (overall survival), nothing is likely to change.
My cases are basically ventilator cases, and Iask, will chmotherapy help get the patient off the ventilator. If not, I will not treat. Nor will I treat anyone with a performance of 3-4 unless there is bound to be a high success rate with treatment.
Not treating is a treatment unto itself, that may provide the unexpected and wonderful of a quality of end of life.

Arnold Wax MD

The Cheerful Oncologist

“Is the Doctor in Today?”

"How Do I Know if It's a First-Class Place?"

Wandering Off the Main Road: Clinical Pathways for Cancer Patients

Helpful Hints for the New Year

The Hateful Patient

“I’m Not Going to Treat Your Cancer”

How I Survived Chemotherapy

“Dear Cancer—Get Lost! I’m on Vacation”

Seven Charts, Seven Lives

A ‘Provider’ or a True Professional?

“I Can’t Afford Any More Advances in Cancer Care, Doc!”

Letter to a Young Smoker From an Oncologist

“This Is My Last Day on Earth”






 
MORE BLOGS

Pain or Feign?
June 10, 2013
50 Shades of Pink—And Why It Helps to Know the Difference
May 17, 2013
I Can’t Talk to You With a Gun in My Face
May 3, 2013
“This Is My Last Day on Earth”
May 2, 2013
Conflicts of Interest in Medicine: What About Ties to Payers?
April 5, 2013
 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
   SEARCH MEDICA RX
   Browse drugs by name:
A B C D E F G H I J
K L M N O P Q R S T
U V W X Y Z All      
   Search for drugs:
Search

 

 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • A 48-Year-Old Woman With Irregular Vaginal Bleeding
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • ASCO: Dabrafenib Shows Activity in BRAF-Mutated NSCLC Patients
  • Preventing Burnout in Oncology
  • ASCO: Yoga Reduces Insomnia in Breast Cancer Patients Treated With Hormone Therapy
  • Physical Activity Across the Cancer Continuum
  • Exercise After Cancer Diagnosis: Time to Get Moving
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Preventing Exposure to Hazardous Drugs
  • ASCO: Vinegar Screening Significantly Reduces Cervical Cancer Mortality
  • ASCO: Sulforaphane in Prostate Cancer Found Worthy of Further Investigation
  • Study: Recurrent Heartburn Ups Risk for Throat Cancer
  • HER2-Directed Therapy for Metastatic Breast Cancer
  • Accelerated Partial-Breast Irradiation: The Current State of Our Knowledge
  • It’s Time for Clinicians to Reconsider Their Proscription Against the Use of Soyfoods by Breast Cancer Patients
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • ASCO: No Benefit From Avastin in Newly Diagnosed Glioblastoma
Click here to subscribe to our newsletter


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy